Winter Park, Florida — January 20, 2026 — Leads & Copy — Adia Nutrition Inc. (OTCQB: ADIA) announced today that the U.S. Securities and Exchange Commission (SEC) has notified them that its Form 10 registration statement will not be subject to further review, meaning it will become effective February 3, 2026.
The Form 10, originally filed on December 5, 2025, marks a key point in Adia’s plan to transition to full SEC reporting status under the Securities Exchange Act of 1934. Once effective, Adia will become a fully reporting company, giving investors enhanced transparency via regular audited financial disclosures, including annual reports on Form 10-K and quarterly reports on Form 10-Q.
Larry Powalisz, Chief Executive Officer of Adia Nutrition Inc., said this notification from the SEC is a major step forward for Adia Nutrition. Powalisz added that beginning February 3, they’ll be fully reporting, giving investors confidence and transparency, which strengthens their ability to scale stem cell therapies, expand their clinics, grow their labs, and advance critical clinical studies.
The effectiveness of the Form 10 will trigger standard SEC reporting obligations. While this step does not guarantee immediate listing on a national exchange such as Nasdaq, it positions the Company to meet key eligibility requirements as it continues to execute on its growth strategy in regenerative therapies, stem cell treatments, and premium nutritional supplements.
Adia Nutrition is focused on delivering healthcare solutions through its divisions, including Adia Med clinics specializing in advanced stem cell therapies and Adia Labs providing biologic products to healthcare providers.
Investors and stakeholders can access the Form 10 and related filings on the SEC’s EDGAR database at www.sec.gov.
Adia Nutrition Inc. (OTCQB: ADIA), based in Winter Park, Florida, specializes in sales of stem cell and regenerative products, such as AdiaVita and AdiaLink, through its lab division, Adia Labs LLC, which is expanding to include insurance-billable wound care products. Adia is also growing nationwide with Adia Med clinics, specializing in orthopedic, pain management, and wound repair. Adia Med clinics also offer specialized regenerative treatments like stem cell therapies and platelet-rich plasma (PRP), advanced treatments including therapeutic plasma exchange (TPE) and autologous hematopoietic stem cell transplantation (aHSCT), and wound repair services.
Revenue is generated through service fees, product sales, equity stakes, and billing insurance for healthcare treatments. Additionally, Adia Nutrition Inc. invests in aligned businesses such as Cement Factory LLC.
Larry Powalisz can be contacted at ceo@adiamed.com or by phone at 321-788-0850.
Source: Adia Nutrition Inc.
